Last updated on March 2016

Phase 1 Combination Study of MM-151 and MM-121


Brief description of study

This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121 at varying dose levels.

Detailed Study Description

This is a two-part Phase 1, non-randomized, open-label study of MM-151 plus MM-121 in patients with advanced, heregulin-positive lung, head and neck, and colorectal cancers. In part 1 of the study cohorts of 3 or more patients will be treated at escalating doses of MM-151 in combination with MM-121 until a maximum tolerated combination dose is identified. In part 2 of the study, patients with be treated with combination dose identified in part 1 of the study.

Clinical Study Identifier: NCT02538627

Contact Investigators or Research Sites near you

Start Over

University of Colorado

Aurora, CO United States
  Connect »

Northside Hospital

Sandy Springs, GA United States
  Connect »

Northwestern

Chicago, IL United States
  Connect »

Vanderbilt

Nashville, TN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.